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HO1a b s t r a c t
Glutamate is the major excitatory neurotransmitter in the brain and over-stimulation of the glutamate
receptors, NMDA, AMPA and kainate (KA), may cause neuronal death in epilepsy, seizures and neurode-
generative diseases. Mitochondria have critical cellular functions that inﬂuence neuronal excitability,
such as regulation of Ca2+ homeostasis and ATP production to maintain Na+K+-ATPase in the central
nervous system (CNS). However, mitochondria are also the primary site of reactive oxygen species
(ROS) production, and oxidative stress can induce cellular damage. Resveratrol, a polyphenol found in
grapes and wines, presents antioxidant and neuroprotective effects on brain pathologies. This study
sought to determine the neuroprotective effect of resveratrol against glutamate toxicity in acute
hippocampal slices, using speciﬁc inhibitors of glutamate channels, and to investigate the targets of glu-
tamate excitotoxicity, such as mitochondrial membrane potential (DWm), Na+K+-ATPase and glutamine
synthetase (GS) activity. Resveratrol decreases intracellular ROS production, most likely by mechanisms
involving NMDA, AMPA/KA, intracellular Ca2+ and the heme oxygenase 1 (HO1) pathway, and prevents
mitochondrial dysfunction and impairments in Na+K+-ATPase and GS activity after glutamate activation.
Taken together, these results show that resveratrol may exhibit an important neuroprotective mecha-
nism against neuropsychiatric disorders, focusing on mitochondrial bioenergetics and oxidative stress,
as well as inhibitory effects on ionic channels.
 2014 Elsevier Ltd. All rights reserved.+1. Introduction
Hippocampal slices have been widely used to investigate the
electrophysiological and biochemical parameters of the Central
Nervous System (CNS), due to partially preserved neuron-astrocyte
circuitry with a suitable control of extracellular medium (Nardin
et al., 2009; Thomazi et al., 2004, 2008). Morphological studies
have conﬁrmed the integrity of a large number of synaptic termi-
nals, including glial cells (Nagy and Li, 2000). The use of brain slices
does have some limitations that are inherent in the use of isolated
neuronal and/or glial cells (Aitken et al., 1995; de Almeida et al.,
2008; Nagy and Li, 2000; Nardin et al., 2009).
Glutamate is the major excitatory neurotransmitter in the brain
(Danbolt, 2001). Extracellular glutamate is normally kept at lowlevels by Na -dependent transport into glia and neurons (Anderson
and Swanson, 2000; Danbolt, 2001). Excessive glutamate stimula-
tion or persistent activation of glutamate-gated ion channels may
cause neuronal degeneration in experimental models of epilepsy,
seizures, ischemia, trauma and neurodegenerative diseases (Coyle
and Puttfarcken, 1993; Friedman et al., 1994; Gupta et al., 2002;
Maragakis and Rothstein, 2006). Ionotropic glutamate receptors,
N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) and kainate (KA), are the predom-
inant receptors at most excitatory synapses (Coyle and Puttfarcken,
1993). The overactivation of these receptors and disrupted gluta-
mate homeostasis has been recognized to play a prominent role
in the development and generation of neurological diseases (Lau
and Tymianski, 2010). Furthermore, activation of an NMDA recep-
tor under depolarizing conditions permits Ca2+ to ﬂow through its
channels, thus increasing the inﬂux of Ca2+ and leading to neuronal
degeneration (Carmignoto et al., 1998; Coyle and Puttfarcken,
1993; Ding et al., 2007).
Oxidative stress and mitochondrial metabolic dysfunction are
involved in neuronal death (Halliwell, 2006). Mitochondria have
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including production of adenosine triphosphate (ATP), fatty acid
oxidation, neurotransmitter biosynthesis, and regulation of Ca2+
homeostasis (Halliwell, 2007; Rosenstock et al., 2004; Waldbaum
and Patel, 2010). The majority of ATP produced by the mitochon-
dria is utilized to maintain Na+K+-ATPase in the CNS (Lingrel,
1992; Waldbaum and Patel, 2010). However, mitochondria are
the primary site of reactive oxygen species (ROS) production.
ROS overproduction generates oxidative stress, and this condition
can affect the functioning of cellular macromolecules, such as lip-
ids, proteins and nucleic acids (Halliwell, 2006, 2007). Glutamate
exposure may induce overactivation of NMDA-type glutamate
receptors and may increase Ca2+ inﬂux into neurons. This Ca2+
can be taken up by mitochondria, where it may stimulate the gen-
eration of oxidative/nitrosative species that damage the mitochon-
dria and the cell (Nicholls, 2008).
Resveratrol (3,5,40-trihydroxy-trans-stilbene), a redox active
compound, is a phytoalexin found in a wide range of dietary
sources, including grapes, peanuts and wine (especially red
wine); it exhibits antioxidant, anti-inﬂammatory, cardioprotec-
tive, estrogenic and antitumoral activities (Baur and Sinclair,
2006; Bobermin et al., 2012; Park et al., 2012; Pervaiz, 2003;
Quincozes-Santos and Gottfried, 2011; Yang et al., 2013). Resve-
ratrol also presents neuroprotective properties and has been
investigated in several neurodegenerative models, such as epi-
lepsy, stroke and Alzheimer’s and Parkinson’s diseases (Bastia-
netto and Quirion, 2010; Baur and Sinclair, 2006; Fukui et al.,
2010; Kim et al., 2007; Kumar et al., 2007; Shetty, 2011).
Although the neuroprotective role of resveratrol in the CNS is
well established, the cellular mechanisms underlying resvera-
trol-induced neuroprotection must be better elucidated (Fukui
et al., 2010; Lee et al., 2010).
Classically, glutamate exposure induces activation of NMDA and
AMPA/KA receptors, mitochondrial damage, and, consequently,
oxidative stress (Coyle and Puttfarcken, 1993). These events are
associated with neuropsychiatric disorders. Thus, in this study,
the biochemical parameters and probable mechanisms by which
resveratrol protects hippocampal slices from glutamate excitotox-
icity were evaluated using speciﬁc inhibitors of glutamate-gated
channels. Additionally, glutamate excitotoxicity targets were
investigated, such as mitochondrial membrane potential (DWm),
Na+K+-ATPase and glutamine synthetase (GS) activity.
2. Materials and methods
2.1. Animals
Male Wistar rats (30 days old) were obtained from our breeding
colony (Department of Biochemistry), maintained under controlled
environment (12 h light/12 h dark cycle, 22 ± 1 C, ad libitum access
to food and water). All animal experiments were performed in
accordance with the NIH Guide for the Care and Use of Laboratory
Animals and were approved by the Federal University of Rio
Grande do Sul Animal Care and Use Committee (process number
21215).
2.2. Materials
Resveratrol, chemical reagents, anti-Na+K+-ATPase a-1 and a-3
subunits, anti-b-actin, MTT Formazan, 20-70-dichoroﬂuorescein
diacetate (DCFH) and c-glutamylhydroxamate were purchased
from Sigma (St. Louis, MO, USA). JC-1 was purchased from Gibco/
Invitrogen (Carlsbad, CA, USA). Anti-HO1 was obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). All other chemicals were
purchased from local commercial suppliers.2.3. Preparation and incubation of hippocampal slices
Animals were killed by decapitation, the brains were removed
and placed in cold saline medium with the following composition
(in mM): 120 NaCl; 2 KCl; 1 CaCl2; 1 MgSO4; 25 HEPES; 1 KH2PO4
and 10 glucose, adjusted to pH 7.4 and previously oxygenated for
15 min with O2. The hippocampi were dissected and transverse
slices of 0.3 mm were obtained using a Mcllwain Tissue Chopper.
Slices were then transferred immediately into 24-well culture
plates, each well containing 0.3 mL of physiological medium and
only slice. The medium was changed every 15 min with fresh sal-
ine medium at room temperature (maintained at 25 C). Following
a 120 min equilibration period, the medium was removed and re-
placed with fresh saline containing, or not, 100 lM resveratrol for
30 min at 30 C. After this period, the medium was maintained and
1 mM glutamate was added to the medium for 30 min at 30 C in a
water bath. For all analyzed parameters, the results obtained with
vehicle (0.25% ethanol) were not different from those obtained un-
der control conditions without ethanol.2.4. Membrane integrity and metabolic activity assays
2.4.1. Lactate dehydrogenase assay
The lactate dehydrogenase (LDH) assay was conducted in 50 lL
of extracellular medium using a commercial colorimetric assay
from Doles (Brazil). Results are expressed as percentages of the
control value.2.4.2. Lactate release assay
The lactate release assay was conducted in 100 lL of extracellu-
lar medium using a commercial colorimetric assay from Labtest
(Brazil). Results are expressed as percentages of the control value.2.4.3. MTT reduction assay
Slices were treated with 0.5 mg/mL of MTT for 30 min at 30 C.
The MTT formazan was dissolved in DMSO. Absorbance values
were measured at 560 and 650 nm. Results are expressed as per-
centages of the control value.2.5. Intracellular ROS production
DCFH oxidation was used to measure intracellular ROS produc-
tion (Quincozes-Santos et al., 2009). DCFH-DA (20-70-dichloroﬂuo-
rescein diacetate) is hydrolyzed by intracellular esterases to
dichloroﬂuorescin (DCFH), which is trapped within the cell. This
non-ﬂuorescent molecule is then oxidized to ﬂuorescent dichloro-
ﬂuorescin (DCF) by action of cellular oxidants. To test whether
NMDA and AMPA/KA activation, intracellular Ca2+ signaling, NO
and heme oxygenase 1 (HO1) pathways were involved in the effect
of resveratrol against glutamate-induced increase ROS production,
we used the following speciﬁc inhibitors: Dizocilpine (MK801) –
10 lM, 6-cyano-7-nitroquinoxaline-2-3-dione (CNQX) – 10 lM,
1,2-Bis(2-aminophenoxy)ethane-N,N,N0,N0-tetraacetic acid tetra-
kis(acetoxymethyl ester) (BAPTA-AM) – 10 lM, Nx-nitro-L-argi-
nine methyl ester (L-NAME) – 500 lM, and Zinc Protoporphyrin
IX (ZnPP IX) – 10 lM, for 30 min added together with resveratrol.
After glutamate incubation, slices were treated with DCFH-DA
(10 lM) for 30 min at 30 C. The ﬂuorescence was measured in a
plate reader (Spectra Max GEMINI XPS, Molecular Devices, USA)
with excitation at 485 nm and emission at 520 nm (Quincozes-
Santos et al., 2009). The ROS production was calculated as Unit of
Fluorescence – UF/mg protein and was expressed as percentage
of control.
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Slices were homogenate using lysis solution with 4% SDS, 2 mM
EDTA, 50 mM Tris–HCl, pH 6.8. Equal amounts of proteins from
each sample were boiled in sample buffer [62.5 mM Tris–HCl, pH
6.8, 2% (w/v) SDS, 5% b-mercaptoethanol, 10% (v/v) glycerol,
0.002% (w/v) bromophenol blue] and submitted to electrophoresis
in 10% (w/v) SDS–polyacrylamide gel (Souza et al., 2013). The sep-
arated proteins were blotted onto a nitrocellulose membrane.
Equal loading of each sample was conﬁrmed with Ponceau S stain-
ing (Sigma). The membranes were incubated with polyclonal anti-
HO1 (1:3000), anti-Na+K+-ATPase a-1 and a-3 (1:1000). b-actin
was used as a loading control. After incubating overnight with
the primary antibody at room temperature, membrane was
washed and incubated with peroxidase-conjugated anti-rabbit
immunoglobulin (IgG) at a dilution of 1:1000 for 1 h. The chemilu-
minescence signal was detected using an ECL (Amersham), after
the ﬁlms were scanned and bands were quantiﬁed using the Scion
Image software.2.7. Thiobarbituric acid reactive substances (TBARS) measurement
Thiobarbituric acid reactive substances assay evaluates the oxi-
dative stress assayed for malondialdehyde (MDA), the last product
of lipid breakdown caused by oxidative stress. The assay was per-
formed as previously described (Esterbauer and Cheeseman, 1990).
Brieﬂy, slices were lysed in PBS with KCl (140 mM) and 100 lL of
homogenates were added to 200 lL of cold 10% trichloroacetic acid
(TCA) and 300 lL of 0.67% TBA in 7.1% sodium sulfate and put in a
boiling water bath for 1 h. The mixture was placed in cold water for
3 min. Afterwards, 400 lL of butyl alcohol were added and samples
were centrifuged at 5000g for 5 min. Pink-stained TBARS was
determined in resulting supernatants in a spectrophotometric
microtiter plate reader at 532 nm. A calibration curve was per-
formed using 1,1,3,3-tetramethoxypropane. Results are expressed
as percentages of the control condition.2.8. Mitochondrial membrane potencial – DWm (JC-1 assay)
For determination of the DWm, after resveratrol and glutamate
treatments, slices were incubated for 30 min with JC-1 (5,50,6,60-
tetrachloro-1,10,3,30-tetraethylbenzimidazolylcarbocyanine iodide,
2 lg/mL) (Reers et al., 1995). After, slices were homogenized and
centrifuged, washed once with HBSS and transferred to a 96-well
plate. Fluorescence was measured using excitation and emission
wavelengths of 485 and 540/590 nm, respectively. The DWm was
calculated using the ratio of 590 nm (red ﬂuorescent J-aggre-
gates)/540 nm (green monomeric). Results are expressed as per-
centages of the control condition.2.9. Na+K+-ATPase activity assay
The reaction mixture for Na+K+-ATPase assay contained (in mM)
5 MgCl2, 80 NaCl, 20 KCl and 40 Tris–HCl, pH 7.4, in a ﬁnal volume
of 200 ll. The reaction was initiated by addition of ATP to a ﬁnal
concentration of 3 mM. Controls were carried out under the same
conditions with the addition of 1 mM ouabain. Na+K+-ATPase activ-
ity was calculated by the difference between the two assays
according to the method of Wyse et al. (2000). Released inorganic
phosphate (Pi) was measured by the method of Chan et al. (1986).
Speciﬁc activity of the enzyme was expressed as nmol Pi released
per min per mg of protein.2.10. Glutamine synthetase (GS) activity
The enzymatic assay was performed as previously described
(dos Santos et al., 2006). Brieﬂy, 0.1 mL homogenates solubilized
in 140 mM KCl was added to 0.1 mL of the reaction mixture con-
taining (in mM): 10 MgCl2, 50 L-glutamate, 100 imidazole-HCl buf-
fer (pH 7.4), 10 2-mercaptoethanol, 50 hydroxylamine-HCl and 10
ATP, and incubated for 15 min (37 C). The reaction was stopped by
the addition of 0.4 mL of a solution containing (in mM): 370 ferric
chloride, 670 HCl, and 200 TCA. After centrifugation, the absor-
bance of the supernatant was measured at 530 nm and compared
to the absorbance generated using standard quantities of c-glu-
tamylhydroxamate treated with a ferric chloride reagent. Results
are expressed as percentages of the control condition.
2.11. Protein assay
Protein content was measured using Lowry’s method with bo-
vine serum albumin as a standard (Lowry et al., 1951).
2.12. Statistical analyses
Data were statistically analyzed using two-way analysis of var-
iance (ANOVA), followed by the Tukey’s test. P-values < 0.05 were
considered signiﬁcant. All analyses were performed using the Sta-
tistical Package for Social Sciences (SPSS) software version 15.0.
3. Results
3.1. Effects of resveratrol and glutamate on cellular viability
The integrity and metabolic activities were evaluated by mea-
suring LDH extracellular content, lactate release and MTT reduc-
tion. The treatment of hippocampal slices with 1 mM glutamate
for 30 min did not cause loss of cellular integrity, as demonstrated
by LDH extracellular content (Fig. 1A). However, glutamate expo-
sure induced a decrease in lactate release (23%, P < 0.05) and
MTT reduction (17%, P < 0.05) (Fig. 1B and C, respectively). Resve-
ratrol was able to restore both parameters to their control values,
with no effect per se.
3.2. Resveratrol inhibits ROS accumulation and lipid peroxidation
induced by glutamate
Resveratrol alone decreased ROS production by approximately
14% (P < 0.05) compared to the control conditions (Table 1). Resve-
ratrol was able to partially prevent the increased intracellular ROS
accumulation that is typically induced by glutamate and also low-
ered DCFH levels from 127 ± 9% to 103 ± 9% (P < 0.01), indicating an
antioxidant role (Table 1). Classically, glutamate induces oxidative
stress and oxidative cell death through mechanisms that are
dependent upon ROS production and/or excessive activation of
glutamate receptors. Thus, the probable mechanisms by which res-
veratrol inhibited intracellular ROS production were tested. First,
the hippocampal slices were treated with the following molecules:
(i) MK801, (ii) CNQX, (iii) BAPTA-AM, (iv) L-NAME and (v) ZnPP IX.
With the exception of ZnPP IX, an HO1 inhibitor, the molecules
attenuated the glutamate-induced oxidative stress (Table 1). More-
over, the co-incubation of resveratrol with MK801, CNQX, BAPTA-
AM and L-NAME potentiated the attenuation of ROS accumulation
induced by glutamate, indicating the involvement of NMDA and
AMPA/KA activation and intracellular Ca2+ signaling and NO path-
way in the neuroprotective effect of resveratrol (Table 1). Notably,
the control, including inhibitors per se, is indicated as a percentage.
Additionally, resveratrol seems to require HO1 for antioxidant
activity. Furthermore, the expression of HO1 was investigated in
Fig. 1. Effects of resveratrol on cellular viability. Hippocampal slices were pre-
treated in either the absence or presence of 100 lM resveratrol (RSV), for 30 min at
30 C, followed by the addition of 1 mM glutamate (GLU) for 30 min/30 C. LDH
extracellular (A), lactate release (B) and MTT reduction (C) were measured as
described in Section 2. Data are expressed as percentages of the control condition
and represent the mean ± S.E.M of 4 independent experimental determinations
performed in triplicate and analyzed statistically by two-way ANOVA, followed by
the Tukey’s test. (a) Indicates signiﬁcant differences from the control values
(P < 0.05) and (b) indicates signiﬁcant differences from glutamate (P < 0.05).
Fig. 2. Effect of resveratrol on lipid peroxidation. Hippocampal slices were pre-
treated in either the absence or presence of 100 lM resveratrol (RSV) for 30 min at
30 C, followed by the addition of 1 mM glutamate (GLU) for 30 min/30 C. TBARS
levels were measured as described in Section 2. Data are expressed as percentages
of the control condition and represent the mean ± S.E.M of 4 independent
experimental determinations performed in triplicate and analyzed statistically by
two-way ANOVA, followed by the Tukey’s test. (a) Indicates signiﬁcant differences
from the control (P < 0.05) and (b) indicates signiﬁcant differences from glutamate
(P < 0.05).
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served (data not shown).
Glutamate exposure also induced increased MDA levels (20%) in
hippocampal slices (Fig. 2). Resveratrol completely prevented this
effect (from 120 ± 12% to 101 ± 9%, P < 0.05; Fig. 2). Resveratrol
alone also decreased lipid peroxidation (12%).
3.3. Effect of resveratrol on DWm
Mitochondria have emerged as a key regulator of oxidative
stress and cytotoxicity. As expected, glutamate reduced DWm byTable 1
Effects of resveratrol on ROS production.
NONE MK801 CNQX
Control 100 ± 8 100 ± 8 100 ± 8
RSV 86 ± 7 a,b 85 ± 7 a,b 88 ± 9
GLU 127 ± 9 a 107 ± 8 b 104 ± 8
RSV + GLU 103 ± 9 b 84 ± 7 a,b 87 ± 7
Hippocampal slices were pre-treated for 30 min in either the absence or presence of 100 l
L-NAME, 10 lM ZnPP IX for 30 min at 30 C, followed by the addition of 1 mM glutamate
Section 2. Data are expressed as percentages of the control condition and represent the m
and analyzed statistically by two-way ANOVA, followed by the Tukey’s test.
a Indicates signiﬁcant differences from the control values (P < 0.05).
b Indicates signiﬁcant differences from glutamate (P < 0.05).approximately 35%, inducing mitochondrial dysfunction, and res-
veratrol completely prevented this effect (Fig. 3). Resveratrol per
se did not affect DWm.
3.4. Resveratrol protected against impaired Na+K+-ATPase activity
typically induced by glutamate
As shown in Fig. 4A, glutamate exposure signiﬁcantly reduced
Na+K+-ATPase activity in the hippocampal slices compared to the
controls from 840 ± 64 to 613 ± 39 nmol Pi/min/mg of protein.
Pre-treatment with resveratrol restored Na+K+-ATPase activity to
values near the control levels. Resveratrol alone had no effect on
Na+K+-ATPase. The a subunit is the catalytic subunit of Na+K+-ATP-
ase in the CNS (Lingrel, 1992). Here, it is demonstrated that treat-
ments of resveratrol and glutamate did not change the expression
of the a-1 or a-3 subunits of Na+K+-ATPase protein (Fig. 4B).
3.5. Resveratrol increased GS activity
Once taken up by astrocytes, glutamate is converted into gluta-
mine by GS (EC 6.3.1.2). Glutamate exposure decreased GS activity
by about 25% compared to control levels. Resveratrol completely
prevented this effect (from 0.75 ± 0.05 to 0.95 ± 0.8 lmol/mg
protein/h, P < 0.05; Fig. 5). Resveratrol alone had no effect on GS
activity.
4. Discussion
Two broad mechanisms (excessive activation of glutamate
receptors and oxidative stress) converge and provide a ﬁnalBAPTA-AM L-NAME ZnPP IX
100 ± 8 100 ± 8 100 ± 8
a,b 85 ± 9 a,b 78 ± 8 a,b 101 ± 7
b 106 ± 9 b 109 ± 8 b 120 ± 8a
a,b 85 ± 7 a,b 79 ± 8 a,b 117 ± 8a
M resveratrol (RSV) and/or 10 lMMK801, 10 lM CNQX, 10 lM BAPTA-AM, 500 lM
(GLU) for 30 min/30 C. Intracellular ROS production was measured as described in
ean ± S.E.M of 4 independent experimental determinations performed in triplicate
Fig. 3. Effect of resveratrol on DWm. Hippocampal slices were pre-treated in either
the absence or presence of 100 lM resveratrol (RSV) for 30 min at 30 C, followed
by the addition of 1 mM glutamate (GLU) for 30 min/30 C. DWm was measured as
described in Section 2. Data are expressed as percentages of the control condition
and represent the mean ± S.E.M of 4 independent experimental determinations
performed in triplicate and analyzed statistically by two-way ANOVA, followed by
the Tukey’s test. (a) Indicates signiﬁcant differences from the control (P < 0.05) and
(b) indicates signiﬁcant differences from glutamate (P < 0.05).
Fig. 4. Effect of resveratrol on Na+K+-ATPase. Hippocampal slices were pre-treated
in either the absence or presence of 100 lM resveratrol (RSV) for 30 min at 30 C,
followed by the addition of 1 mM glutamate (GLU) for 30 min/30 C. Na+K+-ATPase
activity (A) and Na+K+-ATPase expression (B) were measured as described in
Section 2. Data for the activity represent the mean ± S.E.M of 4 independent
experimental determinations performed in triplicate, and for immunocontent, they
are expressed as percentages of the control (2 experimental determinations
performed in duplicate). Data were analyzed statistically by two-way ANOVA,
followed by the Tukey’s test. (a) Indicates signiﬁcant differences from the control
(P < 0.05) and (b) indicates signiﬁcant differences from glutamate (P < 0.05).
Fig. 5. Effect of resveratrol on GS activity. Hippocampal slices were pre-treated in
either the absence or presence of 100 lM resveratrol (RSV) for 30 min at 30 C,
followed by the addition of 1 mM glutamate (GLU) for 30 min/30 C. GS activity was
measured as described in Section 2. Data represent the mean ± S.E.M of 4
independent experimental determinations performed in triplicate and analyzed
statistically by two-way ANOVA followed by the Tukey’s test. (a) Indicates
signiﬁcant differences from the control (P < 0.05) and (b) indicates signiﬁcant
differences from glutamate (P < 0.05).
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1993). Furthermore, several pathologies, such as epilepsy, ischemia
and Parkinson’s and Alzheimer’s diseases impair glutamate metab-
olism and antioxidant defenses through consequent cellular dam-
age (Coyle and Puttfarcken, 1993; Fukui et al., 2010; Halliwell,
2006; Lalo et al., 2006). Glutamate-induced excitotoxicity via
NMDA and AMPA/KA receptors is closely correlated with epilepsy.
Moreover, the removal of pathological ROS during the course of a
brain disorder seems to be a viable approach to neuroprotection
(Waldbaum and Patel, 2010). In this sense, resveratrol, a well-
established antioxidant, may be used as a neuroprotective
molecule. Here, it is demonstrated that resveratrol decreases intra-
cellular ROS production and lipid peroxidation and also prevents
mitochondrial dysfunction and impairments in Na+K+-ATPase and
GS in hippocampal slices after glutamate activation as well as its
the putative neuroprotective mechanism.4.1. Oxidative stress and metabolic changes
High glutamate concentrations induce oxidative-nitrosative
stress, which can lead to lipid, protein and DNA oxidation, causing
cellular damage (Coyle and Puttfarcken, 1993; Moldzio et al.,
2013). It is important to emphasize that in this in vitro model of
glutamate injury, only metabolic alterations were induced; signif-
icant cell death was not observed, but metabolic alterations could
lead to future cell death. Here, under glutamate exposure, meta-
bolic mitochondrial status (as measured by MTT) and extracellular
lactate were decreased. This data could indicate the lack of an en-
ergy substrate for the CNS, because lactate can be released from
astrocytes in extracellular space through monocarboxylate trans-
porters (MCT) and be used as an energy substrate for neurons in
oxidative-derived ATP production (Belanger et al., 2011; Pellerin
et al., 2002). Resveratrol was able to restore lactate levels and thus
can modulate cellular metabolism and energy in the brain.
Many studies have shown that resveratrol possesses direct rad-
ical scavenging activity (Bobermin et al., 2012; de Almeida et al.,
2007; Huang et al., 2011; Quincozes-Santos et al., 2009). Accord-
ingly, resveratrol could protect hippocampal slices from gluta-
mate-induced excitotoxicity, which results in increased ROS
accumulation. Our group has shown that resveratrol is able to de-
crease intracellular ROS production in glial cells under different
oxidative stimuli (Bobermin et al., 2012; Quincozes-Santos et al.,
2013, 2009; Quincozes-Santos and Gottfried, 2011). Moreover, res-
veratrol per se also decreases intracellular ROS production and lipid
peroxidation. Nardin et al. demonstrated that during the standard-
ization of hippocampal slices for ex vivo assays, metabolic ‘‘recov-
ery’’ is associated with cellular alterations, commonly varying from
15 to 120 min (depending on the experimental assay). Thus, in this
length of time, an increase in ROS production/lipid peroxidation
could have been prevented by resveratrol.
HO1 is a protein by which resveratrol can induce neuroprotec-
tive effects (Bastianetto and Quirion, 2010; Quincozes-Santos et al.,
2013; Sakata et al., 2010). Furthermore, a relationship exists be-
tween HO1 and NOS. The nuclear factor-erythroid-2-related factor
2 (Nrf2) regulates HO1 transcription, which acts a scavenger of NO
and an inhibitor of iNOS (Wakabayashi et al., 2010). Here, resvera-
trol presented more effective results than L-NAME, an iNOS inhib-
itor, in its protection against ROS formation induced by glutamate.
Furthermore, the current group recently reported that resveratrol
modulates HO1 and iNOS expression in glial cells (Quincozes-San-
tos et al., 2013). Therefore, HO1 can also be critical to signaling the
antioxidant response of resveratrol (Sakata et al., 2010). Thus, in
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Nrf2/HO1 system may be therapeutic for epilepsy, resveratrol has
emerged as a new potential treatment for this condition (Mazzufe-
ri et al., 2013).
4.2. Ionic channels
The overstimulation of the neurotransmitter glutamate, to-
gether with other factors, can promote oxidative stress in neural
cells, which is commonly associated with neurological disorders
(Lau and Tymianski, 2010). Glutamate receptors activation in-
creases the inﬂux of Ca2+, activating proteases and stimulating
NOS, which then catalyzes the synthesis of NO from L-arginine
(Calabrese et al., 2007; Coyle and Puttfarcken, 1993). NO can be-
come noxious when interacting with superoxide anions, leading
to overproduction of the powerful oxidant species peroxynitrite
(Bolanos and Almeida, 2006; Moncada and Bolanos, 2006). Here,
we demonstrated that resveratrol potentiates the decrease in
ROS production caused by NMDA and AMPA/KA inhibitors and
intracellular Ca2+ chelator. Thus, these results indicate that resve-
ratrol may partially block the overproduction of ROS in different
steps of the excitotoxicity cascade induced by glutamate exposure
associated with Ca2+ inﬂux. The indirect effects of resveratrol on
NMDA and AMPA receptors may indicate inhibition of glutamate-
mediated excitation in in vitro preparations and animal models.
Moreover, resveratrol treatment signiﬁcantly reduced the in-
creased expression of KA receptor in the hippocampus of epileptic
rats induced by kainic acid (Wu et al., 2009).
Cellular Ca2+ signals are crucial for the control of most physio-
logical processes and cell injuries (Parpura et al., 2012; Rosenstock
et al., 2004; Smaili et al., 2003). Mitochondria, together with the
endoplasmic reticulum, play pivotal roles in regulating intracellu-
lar Ca2+ content. During cellular Ca2+ overload, mitochondria take
up cytosolic Ca2+, which in turn induces the opening of permeabil-
ity transition pores and disrupts DWm (Lin et al., 2007; Parpura
et al., 2012; Rosenstock et al., 2004). After glutamate exposure, res-
veratrol potentiates the effect of BAPTA-AM, decreasing intracellu-
lar ROS levels through excessive Ca2+ activation.
4.3. Molecular targets
Mitochondrial oxidative stress and dysfunction are contributing
factors of various neuropathological conditions (Waldbaum and
Patel, 2010). Here, it was demonstrated that resveratrol prevented
DWm induced by glutamate exposure. Excessive ROS production
induces mitochondrial dysfunction and contributes to neuronal
damage (Waldbaum and Patel, 2010). Glutamate exposure and/or
NMDA activation induces impaired mitochondrial function, in-
creased intracellular Ca2+ overload, peroxynitrite generation and
neuronal death, which are characteristic of neurological disorders
(Bolanos and Heales, 2010; Coyle and Puttfarcken, 1993). Addition-
ally, excessive mitochondrial ROS production can damage DNA,
and resveratrol also presented genoprotective effects for glial cells
(Quincozes-Santos et al., 2010, 2007). Recent evidence indicates
that mitochondrial dysfunction is not merely a consequence of
brain damage, but an active contributor to seizures, epileptogene-
sis and neurodegeneration (Kunz et al., 2000; Waldbaum and Patel,
2010).
Na+K+-ATPase is an enzyme in the cytoplasmatic membrane
that is responsible for the active transport of Na+ and K+ ions in
the CNS, maintaining the ionic gradient necessary for neuronal
excitability and regulation of neuronal cell volume, it consumes
most of the ATP generated in the brain (Dobrota et al., 1999; Lin-
grel, 1992). It has been demonstrated that this enzyme is highly
susceptible to free radical attack, and some reports have shown
that Na+K+-ATPase activity is decreased in cases of epilepsy andAlzheimer’s disease (Silva et al., 2011; Zhang et al., 2013). Exces-
sive ROS production has been reported to inhibit Na+K+-ATPase
activity (Grisar et al., 1992). Resveratrol was able to prevent the de-
crease in Na+K+-ATPase activity in hippocampal slices, as were
other antioxidants to prevent cellular damage in different models
of study (Ferreira et al., 2011; Stefanello et al., 2011).
GS is highly sensitive to oxidative and nitrosative stress and it
has been hypothesized to play an important role in the pathogen-
esis of excitotoxicity. This enzyme is also dependent on ATP and
metal ions for catalysis (Banerjee et al., 2008; Felipo and Butter-
worth, 2002; Hertz, 2006; Hertz and Zielke, 2004). Our group has
previously demonstrated that resveratrol modulates GS activity
and that NO metabolism seems to be related to GS activity failure;
thus, resveratrol can act as a scavenger and may improve GS activ-
ity (Bobermin et al., 2012). Reduction of GS activity and/or expres-
sion was reported in brain models of epilepsy, ischemia and
neurodegenerative diseases (Coulter and Eid, 2012; Mates et al.,
2002; Walton and Dodd, 2007). Furthermore, the decrease in GS
activity is coupled with the decreased capacity of glutamate
metabolism and, consequently, leads to neural damage (Wald-
baum and Patel, 2010).5. Conclusions
Resveratrol, a promising neuroprotective molecule, is able to
protect against neurotoxicity and neuronal death (Fukui et al.,
2010). In this study, we focused on mitochondrial bioenergetics
and oxidative stress. Other antioxidants, such as vitamin C, vitamin
E and N-acetyl-L-cysteine (NAC), have been suggested to exert neu-
roprotective effects, but the effects have been attributed to reduced
lipid peroxidation and/or oxidative damage. Bobermin et al.
showed that resveratrol acted more efﬁciently than vitamin C, L-
NAME and trolox in protecting against ammonia toxicity. Here, it
was demonstrated that resveratrol protected hippocampal slices
against glutamate toxicity by modulating DWm, Na+K+-ATPase
and GS activity. Moreover, resveratrol may activate pathways, such
as HO1, that modulates excitotoxicity, mitochondrial dysfunction,
oxidative stress and neuroinﬂammation. These results are similar
to obtained in C6 glial cell suggesting that glial cells in our brain
slice preparations are resveratrol targets, but further studies using
neuron and astrocyte cultures will be necessary to evaluate if
astrocytes are mediating the resveratrol protection against oxida-
tive stress, particularly investigating localization and activity of
HO1. Although its mechanism of action is not completely clear, this
compound has a strong antioxidant/scavenger activity that pre-
vents NMDA, AMPA/KA and intracellular Ca2+ activation and thus
protects neurons against glutamate-induced neuronal damage.
This study’s data suggest that resveratrol is potentially useful in
neuropsychiatric disorders treatment.Conﬂict of interest
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